Abstract：
In May 2022, mpox began to spread worldwide, posing a serious threat to human public health. Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) is a live attenuated orthopoxvirus vaccine that has been authorized by the U.S. Food and Drug Administration as the vaccine of choice for the prevention of mpox. In this study, we conducted a meta-analysis of all currently published literature on the efficacy and safety of the MVA-BN vaccine in the real world, showing that the MVA-BN vaccine is effective and safe, with efficacy of up to 75% with a single dose and up to 80% with a two-dose vaccine. Meanwhile, we found that subcutaneous injection has lower local and systemic adverse events than intradermal injection, regardless of single- or two-dose vaccination, and subcutaneous injection is better tolerated in children, the elderly, or people with underlying medical conditions. These results have important reference value for clinical practice.
摘要：
2022年5月，水痘开始在全球范围内传播，严重威胁人类的公共健康。改良的VacviniaAnkara-BavariaNordic（MVA-BN）是一种减毒活正痘病毒疫苗，已被美国食品和药物管理局授权为预防水痘的首选疫苗。在这项研究中,我们对目前发表的关于MVA-BN疫苗在现实世界中的有效性和安全性的所有文献进行了荟萃分析，表明MVA-BN疫苗是有效和安全的，单剂量疫苗的效力高达75％，两剂量疫苗的效力高达80％。同时,我们发现皮下注射比皮内注射具有更低的局部和全身不良事件，无论单剂量或双剂量疫苗接种，皮下注射在儿童中的耐受性更好，老年人,或有潜在医疗条件的人。这些结果对临床实践具有重要的参考价值。
